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Abstract
F420 is a unique cofactor present in a restricted range of microorganisms, including mycobacteria. It has been proposed that
F420 has an important role in the oxidoreductive reactions of Mycobacterium tuberculosis, possibly associated with anaerobic
survival and persistence. The protein encoded by Rv0132c has a predicted N–terminal signal sequence and is annotated as
an F420–dependent glucose-6-phosphate dehydrogenase. Here we show that Rv0132c protein does not have the annotated
activity. It does, however, co–purify with F420 during expression experiments in M. smegmatis. We also show that the
Rv0132c–F420 complex is a substrate for the Tat pathway, which mediates translocation of the complex across the
cytoplasmic membrane, where Rv0132c is anchored to the cell envelope. This is the first report of any F420–binding protein
being a substrate for the Tat pathway and of the presence of F420 outside of the cytosol in any F420–producing
microorganism. The Rv0132c protein and its Tat export sequence are essentially invariant in the Mycobacterium tuberculosis
complex. Taken together, these results show that current understanding of F420 biology in mycobacteria should be
expanded to include activities occurring in the extra-cytoplasmic cell envelope.
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Received February 6, 2012; Accepted August 14, 2012; Published October 22, 2012
Copyright:  2012 Bashiri et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Funded by the Health Research Council of New Zealand, the Foundation for Research, Science and Technology of New Zealand and the United States
National Institutes of Health (grant RO1 AI054540). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: en.baker@auckland.ac.nz
Introduction
Tuberculosis (TB) is a devastating and contagious infectious
disease. It is estimated that Mycobacterium tuberculosis (Mtb) bacilli,
the causative agent of this disease, infect one–third of the world’s
population, while TB claims nearly two million lives a year [1].
Complications from co–infection with HIV/AIDS and the rise of
multiple–drug (MDR) and extensively drug–resistant (XDR)
strains of Mtb make TB a worldwide concern [1]. WHO estimates
that there are nearly half a million new cases of MDR–TB each
year; about 5% of the nine million new TB cases of all types [1].
Although some promising anti–TB drugs are in clinical trials, there
have been no new drugs against TB in the last thirty years [2].
Understanding the biochemistry and physiology of active and
persistent TB will help to reveal the basis of pathogenesis, making
it possible to combat the disease more effectively.
The coenzyme F420 is a 5-deazaflavin derivative that has been
recently proposed to play a substantial role in the redox reactions
of Mtb [3]. F420 contains an isoalloxazine chromophore with a side
chain composed of ribitol and phospholactate moieties and a poly–
glutamate tail of variable length (Figure 1A). The isoalloxazine
chromophore of F420 is very similar to that of the flavins (FMN
and FAD), with the major difference being the atoms involved in
the oxidoreductive reactions. Oxidoreduction of F420 is achieved
by hydride transfer between a substrate molecule and C5 of the 5-
deazaflavin moiety, whereas transfer occurs to N5 in FMN and
FAD. Despite its structural similarity to the flavins, F420 is
functionally similar to NAD(P)+, being involved in hydride transfer
reactions [for a review see [4] and references therein].
The number of known F420–dependent proteins in mycobac-
terial species is growing, and a few of such activities have been
experimentally shown, including F420–dependent glucose-6-phos-
phate dehydrogenase (FGD) [5,6], deazaflavin–dependent nitror-
eductase (Ddn) [7,8] and F420H2–dependent reductase (FDR) [9]
activities. Bioinformatic analyses have indicated the presence of
three different F420–dependent families in Mtb with at least 28
members; the luciferase–like monooxygenase (LLM), pyridox-
amine 59-phosphate oxidase (PNPOx), and the deazaflavin–
dependent nitroreductase (DDN) families [3]. We have previously
characterized the structure and function of FGD1 from Mtb and
showed that it has the annotated activity, providing reduced F420
for cell metabolism [5]. The reaction catalysed by FGD1 is
equivalent to the first step in the pentose phosphate pathway,
which normally provides NADPH for reductive biosynthetic
reactions and maintenance of the cellular redox state. The
enzyme Ddn uses the reduced F420 produced by FGD1 to activate
a promising anti–TB prodrug PA–824 [10], which is currently in
the second phase of clinical trials. The physiological role of Ddn,
however, is yet to be identified. It has also been shown that
reduced F420 can convert NO2 to NO in vitro, implying a possible
protective role against nitrosative damage in mycobacteria in vivo
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[11]. All these observations point to the fact that cofactor F420 has
an important role in the physiology, and likely in the pathogenesis,
of Mtb.
The Mtb genome [12] encodes a second protein that is
homologous with FGD1 (36% protein sequence identity), anno-
tated as FGD2. Expression of FGD2 (Rv0132c) is under control of
the sigma factor SigF [13], which is expressed during stationary
growth phase and under stress conditions in vitro [14]. A complete
genomic microarray analysis revealed that Rv0132c was down–
regulated in a DsigF mutant of Mtb in late stationary phase [13].
We set out to determine whether Rv0132c does indeed bind the
coenzyme F420 and whether it has the annotated F420–dependent
glucose-6-phosphate dehydrogenase activity. We also noted that
Rv0132c has a predicted N–terminal signal sequence that contains
motifs suggestive of export via the twin-arginine translocation (Tat)
pathway [15], together with post–translational lipid modification.
Here we investigate the possible significance of the Rv0132c
protein in F420 metabolism in Mtb. We report experimental
evidence regarding the cellular location of Rv0132c, consistent
with post–translational lipidation of the protein. In addition, we
show that the Rv0132c protein does bind the cofactor F420, has a
functional twin–arginine translocation (Tat) signal sequence, and is
exported to the cell envelope by the Tat-dependent pathway.
These results demonstrate that Rv0132c and the Mtb Tat pathway
have a direct role in transferring the cofactor F420 across the
cytoplasmic membrane, and suggest that the known roles of F420
should be expanded to include activities in the cell envelope.
Materials and Methods
Mycobacterial strains and plasmids used in this study are in
Table S1, and primers used in the amplification of the various
constructs are detailed in Table S2. Full methodological details of
bacterial growth, PCR amplification, cloning, homology model-
ing, western blotting and immunoelectron microscopy are given in
the Supporting Information (Text S1).
Sequence data
Sequence data for Rv0132c and its orthologues in various
mycobacterial species were retrieved from the published (www.
ncbi.nlm.nih.gov/gene) and unpublished (http://www.sanger.ac.
uk/cgi-bin/blast/submitblast/mycobacterium) sequences and the
alignments were carried out using CLUSTALW [15].
Protein expression and purification
The ORF encoding Rv0132c was PCR–amplified from Mtb
H37Rv genomic DNA (Text S1). When its amino acid sequence is
compared with the homologous FGD1, Rv0132c has a 38-residue
N-terminal extension, which was predicted by the program
PRED–TAT [16] to be a signal sequence with a twin-arginine
translocation (Tat) motif. For functional analysis, a construct
Rv0132c–D38 was therefore prepared that encodes the Rv0132c
protein without its predicted signal sequence and with an N–
terminal His–tag, cleavable by TEV protease (Text S1). The
Rv0132c protein was expressed in M. smegmatis mc24517 cells
[17,18], grown for four days, after which the cells were lysed in
20 mM HEPES pH 7.5, 150 mM NaCl, 20 mM imidazole and
1 mM b–ME. After centrifugation, Rv0132c was purified from the
supernatant by Ni2+–affinity chromatography, cleavage of the
His–tag and size exclusion chromatography (SEC) using the same
buffer as for lysis (with no imidazole). Analytical SEC was used to
determine the oligomeric state of the purified Rv0132c protein,
using low molecular weight markers (conalbumin, 75 kDa;
ovalbumin, 43 kDa; chymotrypsinogen, 25 kDa; and ribonuclease
A, 13.7 kDa; GE Healthcare) to prepare a standard curve (Figure
S1). The elution volume of Rv0132c protein was then used to
estimate its molecular weight and oligomeric state.
Rv0132c activity experiments
Assays for the annotated FGD activity of Rv0132c were
performed using previously published protocols [5,6], using
appropriate concentrations of the purified Rv0132c, cofactor
F420 (25 mM) and glucose-6-phosphate (0.01–1 mM). The change
in cofactor F420 absorbance at 420 nm was monitored over 5 min
using UV–visible spectroscopy on a SpectraMAX microplate
spectrophotometer (Molecular Devices). The reactions contained
100 mL of 20 mM HEPES pH 7.0, 150 mM NaCl, 1 mM b–ME
and were performed in 96–well format (Greiner bio–one,
Germany).
Figure 1. Molecular structure of cofactor F420. (A) Schematic representation of cofactor F420, where n varies from 2–9 in different
microorganisms. (B) Mass spectrometry analysis of cofactor F420 bound to the purified Rv0132c–D38 protein showing the population of species
differing in the number of glutamate residues in the poly-Glu tail.
doi:10.1371/journal.pone.0045003.g001
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Cofactor characterization and F420 preparation
The protein off the gel filtration column was boiled at 100uC for
15 min and centrifuged at 160006g. The resulting supernatant
was adjusted to pH,7 with formic acid and applied to a 10 mg C-
18 reversed phase solid phase extraction (SPE) cartridge. The SPE
cartridge was then washed with 300 mL water and then 150 mL of
50 mM ammonium bicarbonate. The alkaline elution was
collected and concentrated to 10 mL and was then diluted to
20 mL with 20% acetonitrile. The resulting solution was back–
filled into a static nanoelectrospray needle (tip diameter 4 mm)
which was then mounted into a nanoelectrospray interface of a
Finnigan LTQ FT mass spectrometer. Ion trap and ion cyclotron
resonance (ICR) cell data were obtained using a source voltage of
1.3 kV, capillary temperature of 225uC and capillary voltage of
26 V. MS/MS spectra were obtained by isolating key molecular
ions and fragmenting using helium as the collision gas and 35%
collision energy.
The F420 coenzyme was purified from large scale preparations
of M. smegmatis mc24517 cells expressing Mtb–FGD1 or FbiABC
(three ORFs involved in the biosynthesis of F420) constructs [4] in a
19.5–liter fermentor (New Brunswick Scientific). The purification
was carried out using solvent extraction, ion exchange, adsorption
and desalting chromatography steps as described before [4,19].
The absorption of F420 at 400 nm (e400 = 25 mM
21 cm21) was
used to determine its concentration [20].
Tat–dependent translocation of Rv0132c
The first 42 residues of the Rv0132c protein were used to
generate a BlaC fusion construct (Rv0132cSS–’BlaC), which was
then transformed into M. smegmatis DlysDblaS (PM759) [21], M.
smegmatis DlysDblaSDtatA (JM578) [22] and M. tuberculosis DblaC
(PM638) [21] (Text S1). Transformants were tested for carben-
icillin resistance by plating on media containing 50 mg/mL
carbenicillin, as an indication of Tat-dependent export of ’BlaC
fusion constructs. For M. smegmatis and Mtb strains 500–1000
bacteria were plated on +/2 carbenicillin containing agar.
Carbenicillin resistance (+) was scored when .90% of colonies
plated grew on carbenicillin, whereas carbenicillin sensitivity (2)
was defined in strains showing 0% (no single colony growth) on
carbenicillin containing media (Text S1).
As an independent method of proving Rv0132c is exported out
of the cytoplasm by the Tat pathway, epitope-tagged full-length
Rv0132c (Rv0132c-HA) was introduced into M. smegmatis mc2155
(wild type) [23] and JM576 (DtatC mutant) [22]. Cells were
fractionated after lysis and were then used for western blotting
using an anti-HA primary antibody.
Subcellular localization of native Rv0132c in Mtb
The subcellular localization of native Rv0132c in Mtb was
determined by western blotting and immunoelectron microscopy
(Text S1), using polyclonal antibodies raised against purified
Rv0132c. The preimmune serum was used as a control. Whole cell
lysate (WCL) derived from Mtb H37Rv cells was fractionated using
differential ultracentrifugation to yield cell wall (CW), cytoplasmic
membrane (CM), and soluble (SOL) fractions [24]. In addition,
Mtb lipoproteins were prepared using Triton X–114 partitioning
[24,25]. For immunogold microscopy, Mtb H37Ra cells were fixed
and dehydrated in ethanol, pelleted and transferred to fresh resin
in gelatin capsules for polymerization overnight at 60uC. Ultrathin
sections (,80 nm) were cut with a 45 degree diamond knife
(Diatome) on an EM UC6 and collected onto 400–mesh nickel
grids. For immunogold labelling, grids were incubated with either
antiserum or preimmune serum, washed, blotted and transferred
to drops of secondary antibody (goat anti–rabbit labelled with
10 nm gold, Sigma). Grids were washed, stained, air–dried and
viewed in either a Philips CM12 or an FEI Tecnai 12 TEM, both
operating at 120 kV.
Results
Rv0132c is an F420–binding protein
The Rv0132c protein, expressed in M. smegmatis from an
Rv0132c–D38 construct lacking the predicted N–terminal signal
sequence, was purified by Ni–NTA and SEC. The protein eluted
in the Ni–NTA step was resolved as a single band on an SDS–
PAGE gel (Figure 2A). Analysis of the purified protein by
analytical SEC showed that the elution volume corresponded to
a molecular weight of 75 kDa (Figure S1), consistent with a dimer
in solution when compared with the monomer molecular weight of
35.2 kDa. The purified Rv0132c protein had a light yellow color
that was retained after gel filtration, indicating that the source of
the color remained bound to the protein.
To characterize the protein–bound yellow color, the purified
protein was heat–denatured and the resulting yellow supernatant
was analysed by mass spectrometry. This showed that bound F420
is indeed responsible for the yellow color of the protein. The mass
spectrometry identified F420 molecules with varying lengths of
poly–glutamate tail, ranging from 4–8 glutamate residues
(Figure 1B). This corresponds well with the range of F420 species
extracted from wild type M. smegmatis cells [5,19] and implies that
the protein does not discriminate among F420 species with different
numbers of glutamate residues. A similar promiscuity of binding
has recently been shown for the enzyme Ddn, which binds F420-2
and F420-5 with similar affinity [26]. These findings are in line with
our hypothesis, from studies on FGD1, that the length of the F420
poly–glutamate tail may not affect reaction catalysis in F420–
dependent oxidoreductive enzymes [4].
The absorption spectrum of purified Rv0132c (Figure 2B) shows
two absorption peaks, at 400 and 440 nm. In contrast, the F420
extracted from the purified Rv0132c shows a single peak at
420 nm, identical to that of the F420 extracted from M. smegmatis
(Figure 2B). This suggests that in the Rv0132c protein environ-
ment the F420 absorption spectrum is perturbed compared with its
free form. Considering that this recombinant Rv0132c–D38 lacks
its native signal sequence for export and hence is restricted to the
cytosol, our findings indicate that Rv0132c binds the F420 cofactor
in the cytosol, independent of its signal sequence and final
destination.
Rv0132c is incorrectly annotated
Of the two Mtb gene products annotated with FGD activity,
FGD1 has been fully characterized with respect to structure and
function [5]. Activity assays over a range of concentrations of
enzyme and glucose-6-phosphate failed to detect any FGD activity
for Rv0132c, however, under conditions where FGD1 was fully
active (Figure 3). This indicates that Rv0132c is mis-annotated as
an F420-dependent glucose-6-phosphate dehydrogenase. Sequence
alignments and homology modeling of Rv0132c (Text S1; Figure 4)
show that the F420–binding residues identified in FGD1 are also
present in Rv0132c but that there are differences in the substrate
binding site. In particular, three phosphate binding residues in
FGD1, Lys198, Lys259, and Arg283 [5], are not present in
Rv0132c. Superposition of the modeled Rv0132c on to the FGD1
experimental structure (Figure 4B) further shows that helix a9 in
FGD1 is replaced by a smaller loop in Rv0132c, due to a deletion
of four residues in this region. This would expand the active site
cavity for Rv0132c since this helix is part of the structure that caps
the barrel to create the active site cavity [5]. These results suggest
Tat-Mediated Secretion of Cofactor F420
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that whereas Rv0132c, like FGD1, has the ability to bind F420, the
two enzymes probably act on different substrates and catalyze
different reactions. Our results provide experimental confirmation
for the previous bioinformatic prediction that the Rv0132c protein
would not have the annotated activity, based on sequence
homology [27]. We conclude that Mtb possesses just a single
enzyme with demonstrated FGD activity (FGD1) and suggest that
the suffix 1 should be removed from FGD1 to prevent further
confusion with the incorrectly–annotated FGD2.
Rv0132c and its signal sequence are conserved in
pathogenic mycobacteria
Analysis of the Rv0132c sequence (Figure 4A) using the
program PRED–TAT [16] predicts a 40-residue N-terminal
signal sequence, with a twin-arginine translocation (Tat) motif.
The signal sequence also contains a cysteine residue, within a
lipobox motif, that implicates Rv0132c as a lipoprotein [27]
destined for anchoring to the cell envelope after the post–
translational addition of a lipid moiety. Although lipoproteins are
mainly translocated across the cytoplasmic membrane using the
Sec pathway, it has been reported that some lipoproteins are
exported by the Tat system [28,29,30,31,32].
Sequence searches show that all members of the Mtb complex
(M. tuberculosis, M. bovis, M. africanum, M. canetti and M. microti) have
homologues of Rv0132c with full conservation (99–100% identity)
of the mature protein sequence and the signal sequence, including
the Tat motif. Other pathogenic microbacteria such as M. kansasii,
M. avium and M. avium subsp. paratuberculosis have homologues with
lower sequence identity (75–80%) that in most cases retain the Tat
export sequence. In contrast, non-pathogenic mycobacteria such
as M. smegmatis have homologues of Rv0132c that are of much
lower sequence identity (30–40%) and all appear to lack a Tat
signal sequence.
Rv0132c possesses a functional Tat signal sequence
The Tat pathway is responsible for transporting folded proteins
across the cytoplasmic membrane [33], being different from the
Sec pathway, which transports proteins in an unfolded state [34].
Proteins are targeted to the Tat protein translocase, which includes
three integral membrane proteins, TatA, TatB and TatC, using an
N–terminal signal sequence containing a twin–arginine motif [35].
While the putative Rv0132c signal sequence resembles a Tat
export sequence, past studies show that bioinformatic predictions
of Tat substrates are problematic and experimental validation of
Tat export is critical [36]. Of four tested programs to predict Tat
signal sequences, PRED–TAT [16] was the only one to predict
Rv0132c protein to be a Tat substrate, emphasizing the need for
Figure 2. SDS–PAGE and UV–visible spectra of the purified Rv0132c–D38 protein. (A) SDS–PAGE gel of the purified Rv0132c–D38 protein.
(B) UV-visible spectra for purified Rv0132c (0.5 mg/mL in PBS, red), F420 extracted from M. smegmatis cells (50 mM in PBS, green) and F420 extracted
from the purified Rv0132c (blue). M: molecular weight markers (kDa).
doi:10.1371/journal.pone.0045003.g002
Figure 3. Functional assay of Rv0132c–D38 protein. The FGD
activity was assessed for Rv0132c–D38 protein and Mtb–FGD1 as a
positive control. Mtb–FGD1 shows a decrease at 420 nm absorbance
(green and red lines), whereas Rv0132c–D38 protein indicated no
change in the absorbance (yellow and blue lines). The same results
were observed using various concentrations of Rv0132c–D38 protein in
the presence of different concentrations of glucose-6-phpsphate. The
graph shows assays containing 1 mM of each enzyme, 25 mM F420 with
0.1 mM (green and yellow lines) and 1 mM (red and blue lines) glucose-
6-phosphate.
doi:10.1371/journal.pone.0045003.g003
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an experimental approach for verification. To this end we used a
BlaC reporter system [22,36,37] to determine whether Rv0132c
has a functional Tat signal sequence [22]. BlaC of Mtb (and BlaS
for M. smegmatis) is a secreted b–lactamase that confers resistance
to b–lactam antibiotics and can be used as a reporter for Tat–
dependent export. This is because BlaC is normally exported via
the Tat pathway [22] and, when expressed without its signal
sequence, the truncated BlaC (’BlaC) is not exported, and does not
confer b–lactam resistance [22]. In–frame fusion of a functional
Tat signal sequence to ’BlaC, however, rescues export and b–
lactam resistance [22]. In this way, signal sequences can be tested
for their ability to promote Tat–dependent export [22]. Impor-
tantly, the ’BlaC reporter only works with Tat (and not Sec) signal
sequences.
To determine whether Rv0132c is a Tat substrate, we fused its
signal sequence in frame with ’BlaC, forming an Rv0132cSS–
’BlaC construct (Text S1). Whereas M. smegmatis DblaS mutant is
sensitive to carbenicillin, a b–lactam antibiotic, expression of
Rv0132cSS–’BlaC conferred resistance to carbenicillin, indicating
export (Table 1). Similarly, when expressed in M. tuberculosis DblaC,
Rv0132cSS–’BlaC conferred resistance to carbenicillin (Table 1).
When expressed in an M. smegmatis strain lacking the Tat export
channel (DblaSDtatA), Rv0132css–’BlaC failed to confer resistance
to carbenicillin, confirming Tat dependent export (Table 1). The
results obtained for Rv0132cSS–’BlaC were compared with the b–
lactam resistance or sensitivity resulting from published controls:
full length BlaC, truncated ’BlaC, and a Tat–dependent PlcBss–
’BlaC fusion [22]. PlcB is a demonstrated Tat substrate in Mtb and
Figure 4. Structural comparison of Rv0132c with FGD1. (A) Amino acid sequence alignment. The secondary structure elements for FGD1 [5]
are shown above the sequence. FGD1 residues that hydrogen bond with F420 or the phosphate group of glucose-6-phosphate are indicated below
the sequence by F and asterisk, respectively. The twin arginines in the Tat motif and the critical cysteine residue in the lipobox motif are shown in red
in the Rv0132c signal sequence. (B) Superposition of the FGD1 (orange) crystal structure on the modeled Rv0132c (cyan). The F420 cofactor (green)
bound to FGD1 is shown in stick representation. Replacement of helix a9 with a smaller loop extends the active site cavity in Rv0132c. For details of
FGD1 structure see [5].
doi:10.1371/journal.pone.0045003.g004
Table 1. Export of an Rv0132cSS–’BlaC1 fusion protein is dependent on the Tat pathway.
Strain Genotype Carbenicillin Resistance
2
Vector only BlaC ’BlaC1 PlcBss–’Blac Rv0132cSS–’Blac
M. smegmatis PM759 DblaS3 2 + 2 + +
M. smegmatis JM578 DblaSDtatA3 2 2 2 2 2
M. tuberculosis PM638 DblaC4 2 + 2 + +
1’BlaC = truncated BlaC lacking its native signal sequence.
2All strains were resistant to 20 mg/mL kanamycin due to the vector resistance marker. The presence (+) or absence (2) of carbenicillin resistance was determined by
colony growth on LB–agar plates plus 20 mg/mL kanamycin and 50 mg/mL carbenicillin for M. smegmatis and 7AGT plates plus 20 mg/mL kanamycin and 50 mg/mL
carbenicillin for M. tuberculosis. See materials and methods for additional experimental details.
3Carbenicillin resistance was determined after 4–7 days.
4Carbenicillin resistance was determined after 21 days.
doi:10.1371/journal.pone.0045003.t001
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PlcBss–’BlaC is Tat exported and confers b–lactam resistance
[22,36]. Rv0132cSS–’BlaC confers a similar level of b–lactam
resistance as PlcBss–’BlaC. Taken together, these results demon-
strate that Rv0132c has a functional Tat signal sequence.
Rv0132c is exported to the cell envelope by the Tat
pathway
While the ’BlaC reporter experiments demonstrated the
existence of a Tat signal sequence in Rv0132c, additional features
in the mature domain of a protein are required for it to be Tat
exported. This is because the mature domain of Tat-exported
proteins must fold prior to export [38,39]. For this reason, we
additionally tested whether export of the full length Rv0132c
protein occurs via the Tat pathway. Rv0132c with a C-terminal
HA epitope tag was expressed in wild type and DtatC M. smegmatis
(Figure 5). Cells were harvested and lysed, and whole cell lysates
(WCL) were fractionated using differential ultracentrifugation to
generate cell wall (CW), cytoplasmic membrane (CM), and soluble
(SOL) fractions (containing the cytosol). To determine cellular
localization, equal cell equivalents of the fractions were separated
on an SDS-PAGE gel for western blot analysis with anti-HA
antibodies (Text S1). Rv0132c was detected as being exported to
the cell wall and cell membrane fractions in wild type M. smegmatis,
but not in the DtatC mutant where the protein remained in the
soluble cytosolic fraction. This analysis demonstrated that
Rv0132c export is dependent on a functional Tat pathway. The
integrity of the cellular fractions was verified by Western blotting
for GroEL (a cytoplasmic protein) as a control. The cell wall and
cytoplasmic membrane fractions were free of cytoplasmic
contamination, as shown by the lack of GroEL (Figure 5).
Native Rv0132c is targeted to the cell envelope in Mtb
To determine the localization of the native Rv0132c protein in
Mtb, anti–Rv0132c antiserum was used for western blotting and
immunoelectron microscopy experiments (Text S1). Whole cell
lysate (WCL) prepared from Mtb H37Rv cells was fractionated as
above to yield cell wall (CW), cytoplasmic membrane (CM), and
soluble (SOL) fractions. Equal cell equivalents of the fractions were
subjected to western blot analyses, which showed that the native
Rv0132c protein is present in the cell wall and membrane
fractions of Mtb (Figure 6A). Triton X–114 fractionation of Mtb
H37Rv whole cell lysate further showed that the native Rv0132c
protein is present in the detergent–enriched fraction (Figure 6B).
Triton X–114 is a non–ionic detergent which has been used
extensively to partition hydrophilic proteins (i.e. soluble) from
amphiphilic proteins (e.g. lipoproteins and integral membrane
proteins) [40]. Given our prior results demonstrating the presence
of a functional Tat signal sequence on Rv0132c, the Triton X-114
fractionation results are consistent with Rv0132c being a Tat
exported lipoprotein that is exported to the cell envelope. The
lipidation of the Rv0132c protein might also explain the reason for
smeary bands of native Rv0132c in western blots (Figure 6). In
contrast, the recombinant Rv0132c–D38 protein used as a control
cannot be lipidated as it lacks the signal sequence, and shows a
single sharp band. The integrity of the cellular fractions was
verified by western blotting using GroEL antibody as a control for
cytoplasmic contamination; no GroEL signal was detected in the
CW and CM fractions (data not shown).
More evidence of the Rv0132c protein localization was
obtained using immunoelectron microscopy of Mtb H37Ra cells
using anti–Rv0132c antiserum. The results, which are consistent
over a wide range of antiserum concentration, indicate that
Rv0132c is indeed present mainly on the periphery of the cells
(Figure 7).
Discussion
The presence of F420 in mycobacteria has captured much
attention since it was identified as being involved in the activation
of a new anti–TB prodrug PA–824 [41]. In a search for enzymes
Figure 5. Rv0132c export is Tat dependent. Equalized whole cell
lysates (WCL) from wild type (WT) and DtatC M. smegmatis expressing
Rv0132c-HA were fractionated to generate cell wall (CW), cytoplasmic
membrane (CM), and soluble (SOL) fractions. Fractions were separated
by SDS-PAGE and proteins were detected with an anti-HA antibody.
Native GroEL was detected as a cytoplasmic control. Rv0132c-HA was
exported to the CW and CM fractions in wild type M. smegmatis, but it
was not exported in the absence of a functional Tat pathway.
doi:10.1371/journal.pone.0045003.g005
Figure 6. Subcellular localization of Rv0132c protein. (A) Western blots of M. tuberculosis H37Rv subcellular fractions using 1/25000 dilution of
anti–Rv0132c antiserum. Clear signals are found for the WCL, CW and CM fractions, but not for the SOL fraction. (B) Western blots of Triton X–114
treated fractions. The signal is present only in the DET fraction. WCL: whole cell lysate; CW: cell wall; CM: cytoplasmic membrane; SOL: soluble; AQU:
aqueous fraction from Triton X–114 treatment; DET: detergent–enriched fraction from Triton X–114 treatment. In both panels recombinant Rv0132c–
D38 protein (REC) is used as a positive control (0.7 mg).
doi:10.1371/journal.pone.0045003.g006
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involved in PA–824 activation in Mtb, two ORFs were identified,
encoding the enzymes FGD1 [41] and Ddn [10]. It was
subsequently shown that Ddn directly activates the prodrug using
the reduced F420 provided by FGD1 [8]. Although the Mtb
genome has two ORFs encoding proteins annotated as having
FGD activity, FGD1 (Rv0407) and FGD2 (Rv0132c) [12], no
evidence has been reported for any involvement of Rv0132c in the
activation of or resistance towards PA–824. This led us to question
the function of Rv0132c and its F420–dependent nature; either
Rv0132c does not bind F420, or it does not have the annotated
activity, or is physically separated from Ddn where the activation
process occurs.
Our results show unequivocally that Rv0132c is indeed an F420-
binding protein, but that it does not have the annotated FGD
activity. Differences in the substrate-binding region of the active
site are consistent with preference for a different, as yet unknown,
substrate. What sets Rv0132c apart from FGD1, apart from the
differences in the substrate binding site, is its possession (Figure 4A)
of a signal sequence containing a twin–arginine translocation (Tat)
motif, together with a lipobox motif that mediates lipid modifi-
cation to produce a cell envelope–anchored lipoprotein. The full–
length Rv0132c protein sequence, including its Tat motif, is
extremely well conserved (99–100% identity) in the Mtb complex
(M. tuberculosis, M. bovis, M. africanum, M. microti and M. canetti). In
contrast, although homologues of Rv0132c can be found in non-
pathogenic bacterial species they have much lower sequence
identity with Rv0132c (,40%) and lack a Tat motif. This suggests
a role for Rv0132c and its Tat motif in mycobacterial
pathogenesis.
The Tat pathway transports folded proteins across energy–
transducing membranes (e.g. the cytoplasmic membrane) [33],
being different from the Sec pathway, which transports proteins in
an unfolded state [34]. The majority of substrate proteins for the
Tat pathway are enzymes that fold in the cytoplasm and require
cofactor insertion therein prior to export; examples of the
identified cofactors include molydopterin, haem, FAD and
NADP+ [42]. We have shown here that the signal sequence
possessed by Rv0132c, and by implication its homologues in other
pathogenic mycobacteria, is functionally active in Tat-mediated
export. In addition, using M. smegmatis we show Rv0132c is
exported in a Tat-dependent manner and we further show the
native Rv0132c is exported to the cell envelope of pathogenic M.
tuberculosis. This further implies translocation of F420 to the cell
envelope. This is the first report of F420 translocation across the
cytoplasmic membrane in any F420–producing microorganism and
expands the number of Tat–dependent cofactors.
Putting our experimental results together, it is reasonable to
conclude that the Rv0132c protein binds F420 in the cytosol, after
which the Rv0132c–F420 complex is translocated across the
cytoplasmic membrane via the Tat pathway, where the protein is
anchored to the cell envelope. Although the specific biochemical
function of Rv0132c is not yet known, its Tat–dependent
translocation may have evolved in pathogenic mycobacteria to
enable F420 utilization for metabolic or biosynthetic processes in
the dense, lipid–rich cell wall. The conservation of Rv0132c and
its specific Tat signal sequence in the Mtb complex, but not in
non–pathogenic mycobacteria implies that the presence of F420
outside the cytosol is important to the pathogenesis of tuberculosis.
There is growing evidence that F420 plays an important part in
defense against the host immune system and in non-replicating
persistence of Mtb. Transition to the persistent state involves major
changes in energy metabolism [43], and it has been suggested that
F420, with its low redox potential, may have a role in reactions
associated with anaerobic survival [44].
Supporting Information
Figure S1 Calibration curve for estimation of Rv0132c–
D38 molecular weight using analytical SEC. The molecular
weight calibration curve was obtained by plotting Kav values
against LogMW of protein standards. The Kav value determined
from the elution volume of Rv0132c–D38, indicated with *,
corresponded to a molecular weight of 75.4 kDa, which is
indicative of a dimer in solution.
(TIF)
Table S1 Mycobacterial strains and plasmids used in
this study.
(DOCX)
Table S2 Primers used in the amplification of different
Rv0132c constructs.
(DOCX)
Figure 7. Immunoelectron microscopy of the M. tuberculosis H37Ra cells using anti–Rv0132c antiserum. Electron micrographs are shown
in which thin cryo–sectioned Mtb cells are (A) treated with preimmune serum, and (B) treated with anti-Rv0132c antisera at a dilution of 1/200. The
gold particles (indicated by arrowheads) are present mainly on the periphery of the cells in panel B, but are absent from the control panel (A).
doi:10.1371/journal.pone.0045003.g007
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Text S1 Supplementary methods. Details of bacterial
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constructs; western blotting; immunoelectron micros-
copy and homology modeling.
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